参考文献 References
[1] Heinzer R., Vat S., Marques-Vidal P., et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study[J]. The Lancet Respiratory Medicine. 2015;3(4):310-8.
[2] Yeghiazarians Y., Jneid H., Tietjens J. R., et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association[J]. Circulation. 2021;144(3):e56-e67.
[3] Tietjens J. R., Claman D., Kezirian E. J., et al. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy[J]. J Am Heart Assoc. 2019; 8(1): e010440.
[4] Javaheri S., Barbe F., Campos-Rodriguez F., et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences[J]. J Am Coll Cardiol. 2017;69(7):841-58.
[5] Zhao X., Li X., Xu H., et al. Relationships between cardiometabolic disorders and obstructive sleep apnea: Implications for cardiovascular disease risk[J]. J Clin Hypertens (Greenwich). 2019;21(2):280-90.
[6] Stelmach-Mardas M., Mardas M., Iqbal K., et al. Dietary and cardio-metabolic risk factors in patients with Obstructive Sleep Apnea: cross-sectional study[J]. PeerJ. 2017;5:e3259.
[7] Lattimore J. D., Celermajer D. S., Wilcox I. Obstructive sleep apnea and cardiovascular disease[J]. J Am Coll Cardiol. 2003;41(9):1429-37.
[8] Chapman N., Chen C. Y., Fujita T., et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?[J]. J Hypertens. 2010; 28(9): 1796-803.
[9] Iesato K., Tatsumi K., Saibara T., et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome[J]. Circ J. 2007;71(8):1293-8.
[10] Can M., Açikgöz Ş, Mungan G., et al. Serum cardiovascular risk factors in obstructive sleep apnea[J]. Chest. 2006;129(2):233-7.
[11] Li J., Savransky V., Nanayakkara A., et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia[J]. J Appl Physiol (1985). 2007;102(2):557-63.
[12] Zanotti I., Potì F., Cuchel M. HDL AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS AND ANIMALS: LESSONS FROM PRE-CLINICAL MODELS AND CLINICAL STUDIES[J]. Biochim Biophys Acta Mol Cell Biol Lipids. 2021:159065.
[13] Tan K. C., Chow W. S., Lam J. C., et al. HDL dysfunction in obstructive sleep apnea[J]. Atherosclerosis. 2006; 184(2): 377-82.
[14] Feres M. C., Fonseca F. A., Cintra F. D., et al. An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP[J]. Atherosclerosis. 2015; 241(2): 342-9.
[15] Karkinski D., Georgievski O., Dzekova-Vidimliski P., et al. Obstructive Sleep Apnea and Lipid Abnormalities[J]. Open Access Maced J Med Sci. 2017;5(1):19-22.
[16] Adedayo A. M., Olafiranye O., Smith D., et al. Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism[J]. Sleep Breath. 2014;18(1):13-8.
[17] Wu S. A., Kersten S., Qi L. Lipoprotein Lipase and Its Regulators: An Unfolding Story[J]. Trends Endocrinol Metab. 2021;32(1):48-61.
[18] Wood I. S., de Heredia F. P., Wang B., et al. Cellular hypoxia and adipose tissue dysfunction in obesity[J]. Proc Nutr Soc. 2009;68(4):370-7.
[19] Drager L. F., Jun J., Polotsky V. Y. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis[J]. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):161-5.
[20] Barros D., García-Río F. Obstructive sleep apnea and dyslipidemia: from animal models to clinical evidence[J]. Sleep. 2019;42(3).
[21] Li J., Thorne L. N., Punjabi N. M., et al. Intermittent hypoxia induces hyperlipidemia in lean mice[J]. Circ Res. 2005;97(7):698-706.
[22] Roche O., Deguiz M. L., Tiana M., et al. Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia[J]. Nucleic Acids Res. 2016; 44(19): 9315-30.
[23] Prabhakar N. R., Kumar G. K., Peng Y. J. Sympatho- adrenal activation by chronic intermittent hypoxia[J]. J Appl Physiol (1985). 2012;113(8):1304-10.
[24] Bartels N. K., Börgel J., Wieczorek S., et al. Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms[J]. BMC Med. 2007;5:1.
[25] Reiter R. J., Tan D. X., Rosales-Corral S., et al. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives[J]. Mini Rev Med Chem. 2013;13(3):373-84.
[26] Zhang H. M., Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions[J]. J Pineal Res. 2014;57(2):131-46.
[27] Rong B., Wu Q., Reiter R. J., et al. The Mechanism of Oral Melatonin Ameliorates Intestinal and Adipose Lipid Dysmetabolism Through Reducing Escherichia Coli-Derived Lipopolysaccharide[J]. Cell Mol Gastroenterol Hepatol. 2021.
[28] Xu H., Yi H., Guan J., et al. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials[J]. Atherosclerosis. 2014; 234(2): 446-53.
[29] Dorkova Z., Petrasova D., Molcanyiova A., et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome[J]. Chest. 2008;134(4):686-92.
[30] Cuhadaroğlu C., Utkusavaş A., Oztürk L., et al. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea[J]. Lung. 2009; 187(2): 75-81.
[31] Barceló A., Miralles C., Barbé F., et al. Abnormal lipid peroxidation in patients with sleep apnoea[J]. Eur Respir J. 2000; 16(4): 644-7.
[32] Barnaś M., Maskey-Warzęchowska M., Bielicki P., et al. Diurnal and nocturnal serum melatonin concentrations after treatment with continuous positive airway pressure in patients with obstructive sleep apnea[J]. Pol Arch Intern Med. 2017;127(9):589-96.
[33] Robinson G. V., Pepperell J. C., Segal H. C., et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials[J]. Thorax. 2004; 59(9): 777-82.
[34] Michailidis V., Steiropoulos P., Nena E., et al. Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea[J]. Open Cardiovasc Med J. 2011;5:231-8.
[35] 邓华聪, 临床内科杂志刘东方 %J. 肥胖症与脂质代谢[J]. 2003(03):116-8.
[36] Kobayashi J., Nohara A., Kawashiri M. A., et al. Serum lipoprotein lipase mass: clinical significance of its measurement[J]. Clin Chim Acta. 2007;378(1-2):7-12.
[37] 杨秀颖, 张莉, 陈熙, et al. 2型糖尿病周围神经病变机制研究进展[J]. 2016(5):598-602.
[38] Szmyd B., Rogut M., Białasiewicz P., et al. The impact of glucocorticoids and statins on sleep quality[J]. Sleep Med Rev. 2021;55:101380.